Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 07, 2023

Association of Concomitant PPI Use With Outcomes of Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With NSCLC

JAMA Network Open

 

Additional Info

JAMA Network Open
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
JAMA Netw Open 2023 Jul 03;6(7)e2322915, H Kawachi, T Yamada, M Tamiya, Y Negi, Y Goto, A Nakao, S Shiotsu, K Tanimura, T Takeda, A Okada, T Harada, K Date, Y Chihara, I Hasegawa, N Tamiya, M Ishida, Y Katayama, K Morimoto, M Iwasaku, S Tokuda, T Kijima, K Takayama

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading